AbbVie (ABBV) EPS (Basic) Growth (3y) (2015 - 2026)
Powered by 
Analysis
AbbVie (ABBV) EPS (Basic) Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 5.11% |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 21.23% |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 38.72% |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 14.72% |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | -28.08% |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | -36.03% |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 47.44% |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 12.25% |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 13.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.23% |
| Mar 31, 2026 | 109.43% |
| Dec 31, 2025 | -9.75% |
| Sep 30, 2025 | -63.75% |
| Jun 30, 2025 | 0.50% |
| Mar 31, 2025 | -34.01% |
| Dec 31, 2024 | -26.11% |
| Sep 30, 2024 | -21.05% |
| Jun 30, 2024 | 21.34% |
| Mar 31, 2024 | -27.19% |
| Dec 31, 2023 | 173.44% |
| Sep 30, 2023 | -8.31% |
| Jun 30, 2023 | 65.79% |
| Mar 31, 2023 | -26.56% |
| Dec 31, 2022 | -9.63% |
| Sep 30, 2022 | 20.60% |
| Jun 30, 2022 | 1.55% |
| Mar 31, 2022 | 15.20% |
| Dec 31, 2021 | 57.79% |
| Sep 30, 2021 | -0.39% |